Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-09-25

AUTHORS

Pierre-Edouard Debureaux, Myriam Labopin, Anne-Claire Mamez, Simona Lapusan, Francoise Isnard, Rosa Adaeva, Agnès Bonnin, Pierre Hirsch, Francois Delhommeau, Giorgia Battipaglia, Remy Duléry, Florent Malard, Anne Vekhoff, Mohamad Mohty, Ollivier Legrand, Eolia Brissot

ABSTRACT

Optimization of the salvage regimen is required to improve prognosis in primary refractory or relapsed acute myeloid leukemia (AML). In fit patients, a bridge to allogeneic transplant is the primary purpose of salvage. We tested the combination of fractionated gemtuzumab ozogamicin with cytarabine and mitoxantrone (MYLODAM schema) with primary endpoint of efficacy and safety. We also attempted to define predictive factors for survival and response after salvage. We included 58 patients with a median age at salvage of 56 years. The overall response rate was 67%. Leukemia-free survival (LFS) and overall survival (OS) at 2 years was 36% (95% CI: 23–49) and 54% (95% CI: 39–68), respectively. Treatment-related mortality was 7%. Three veno-occlusive diseases (SOS/VOD) occurred during salvage. In the allogeneic group of 28 patients (48%), LFS and OS at 2 years was 57 % (95% CI: 36.3–77.5) and 69 % (95% CI: 49.3–88.7), respectively. Incidences of nonrelapse mortality, grade II–IV acute graft-versus-host disease (GVHD) and chronic GVHD were 16%, 40%, and 45%, respectively. A GO-based intensive regimen is a viable option for salvage therapy and a feasible schedule as a bridge to allogeneic transplant. More... »

PAGES

452-460

References to SciGraph publications

  • 2003-10-09. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program in LEUKEMIA
  • 2011-02-22. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia in LEUKEMIA
  • 2017-01-16. Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT in BONE MARROW TRANSPLANTATION
  • 2019. Current Status and Perspectives of Irradiation-Based Conditioning Regimens for Patients with Acute Leukemia Undergoing Hematopoietic Stem Cell Transplantation in CLINICAL HEMATOLOGY INTERNATIONAL
  • 2016-05-16. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation in BONE MARROW TRANSPLANTATION
  • 2006-10-19. High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group in LEUKEMIA
  • 2017-01-19. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure in LEUKEMIA
  • 2017-06-24. Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT in JOURNAL OF HEMATOLOGY & ONCOLOGY
  • 2016-12-23. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? in ANNALS OF HEMATOLOGY
  • 2019. Management of AML Beyond “3 + 7” in 2019 in CLINICAL HEMATOLOGY INTERNATIONAL
  • 2016-08-18. Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia in NATURE COMMUNICATIONS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1038/s41409-019-0690-2

    DOI

    http://dx.doi.org/10.1038/s41409-019-0690-2

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1121220442

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/31554931


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aminoglycosides", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antibodies, Monoclonal, Humanized", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antineoplastic Combined Chemotherapy Protocols", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cytarabine", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Gemtuzumab", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Hematopoietic Stem Cell Transplantation", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Leukemia, Myeloid, Acute", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Salvage Therapy", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Debureaux", 
            "givenName": "Pierre-Edouard", 
            "id": "sg:person.07456502030.19", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07456502030.19"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sorbonne Universit\u00e9, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462844.8", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
                "Sorbonne Universit\u00e9, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Labopin", 
            "givenName": "Myriam", 
            "id": "sg:person.0762572112.39", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762572112.39"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mamez", 
            "givenName": "Anne-Claire", 
            "id": "sg:person.01316330650.26", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316330650.26"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lapusan", 
            "givenName": "Simona", 
            "id": "sg:person.01025216261.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025216261.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Isnard", 
            "givenName": "Francoise", 
            "id": "sg:person.010506014074.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010506014074.64"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Adaeva", 
            "givenName": "Rosa", 
            "id": "sg:person.012677511734.74", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012677511734.74"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Bonnin", 
            "givenName": "Agn\u00e8s", 
            "id": "sg:person.016332521016.91", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016332521016.91"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019h\u00e9matologie biologique, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Sorbonne Universit\u00e9, Paris, France", 
                "Service d\u2019h\u00e9matologie biologique, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Hirsch", 
            "givenName": "Pierre", 
            "id": "sg:person.01176400561.73", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176400561.73"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019h\u00e9matologie biologique, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Sorbonne Universit\u00e9, Paris, France", 
                "Service d\u2019h\u00e9matologie biologique, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Delhommeau", 
            "givenName": "Francois", 
            "id": "sg:person.0774547707.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774547707.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Battipaglia", 
            "givenName": "Giorgia", 
            "id": "sg:person.01222046703.79", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222046703.79"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dul\u00e9ry", 
            "givenName": "Remy", 
            "id": "sg:person.01250665275.99", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250665275.99"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sorbonne Universit\u00e9, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462844.8", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
                "Sorbonne Universit\u00e9, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Malard", 
            "givenName": "Florent", 
            "id": "sg:person.0751372141.23", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751372141.23"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.412370.3", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Vekhoff", 
            "givenName": "Anne", 
            "id": "sg:person.01362131264.28", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362131264.28"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sorbonne Universit\u00e9, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462844.8", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
                "Sorbonne Universit\u00e9, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Mohty", 
            "givenName": "Mohamad", 
            "id": "sg:person.0644135047.33", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644135047.33"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sorbonne Universit\u00e9, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462844.8", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
                "Sorbonne Universit\u00e9, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Legrand", 
            "givenName": "Ollivier", 
            "id": "sg:person.0752753564.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Sorbonne Universit\u00e9, Paris, France", 
              "id": "http://www.grid.ac/institutes/grid.462844.8", 
              "name": [
                "Service d\u2019H\u00e9matologie Clinique et de Th\u00e9rapie cellulaire, H\u00f4pital Saint Antoine, APHP, Paris, France", 
                "Sorbonne Universit\u00e9, Paris, France"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Brissot", 
            "givenName": "Eolia", 
            "id": "sg:person.01037550106.72", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037550106.72"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2991/chi.d.190316.001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113600609", 
              "https://doi.org/10.2991/chi.d.190316.001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2016.302", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1023654702", 
              "https://doi.org/10.1038/bmt.2016.302"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13045-017-0498-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1086152596", 
              "https://doi.org/10.1186/s13045-017-0498-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ncomms12475", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008017504", 
              "https://doi.org/10.1038/ncomms12475"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2403135", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042288603", 
              "https://doi.org/10.1038/sj.leu.2403135"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.leu.2404434", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008085123", 
              "https://doi.org/10.1038/sj.leu.2404434"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2991/chi.d.190218.002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1113603473", 
              "https://doi.org/10.2991/chi.d.190218.002"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2011.13", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021686648", 
              "https://doi.org/10.1038/leu.2011.13"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00277-016-2899-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015754901", 
              "https://doi.org/10.1007/s00277-016-2899-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bmt.2016.130", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017627248", 
              "https://doi.org/10.1038/bmt.2016.130"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/leu.2017.23", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007318859", 
              "https://doi.org/10.1038/leu.2017.23"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-09-25", 
        "datePublishedReg": "2019-09-25", 
        "description": "Optimization of the salvage regimen is required to improve prognosis in primary refractory or relapsed acute myeloid leukemia (AML). In fit patients, a bridge to allogeneic transplant is the primary purpose of salvage. We tested the combination of fractionated gemtuzumab ozogamicin with cytarabine and mitoxantrone (MYLODAM schema) with primary endpoint of efficacy and safety. We also attempted to define predictive factors for survival and response after salvage. We included 58 patients with a median age at salvage of 56 years. The overall response rate was 67%. Leukemia-free survival (LFS) and overall survival (OS) at 2 years was 36% (95% CI: 23\u201349) and 54% (95% CI: 39\u201368), respectively. Treatment-related mortality was 7%. Three veno-occlusive diseases (SOS/VOD) occurred during salvage. In the allogeneic group of 28 patients (48%), LFS and OS at 2 years was 57 % (95% CI: 36.3\u201377.5) and 69 % (95% CI: 49.3\u201388.7), respectively. Incidences of nonrelapse mortality, grade II\u2013IV acute graft-versus-host disease (GVHD) and chronic GVHD were 16%, 40%, and 45%, respectively. A GO-based intensive regimen is a viable option for salvage therapy and a feasible schedule as a bridge to allogeneic transplant.", 
        "genre": "article", 
        "id": "sg:pub.10.1038/s41409-019-0690-2", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1096890", 
            "issn": [
              "0268-3369", 
              "1476-5365"
            ], 
            "name": "Bone Marrow Transplantation", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "2", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "55"
          }
        ], 
        "keywords": [
          "leukemia-free survival", 
          "acute myeloid leukemia", 
          "overall survival", 
          "gemtuzumab ozogamicin", 
          "allogeneic transplants", 
          "myeloid leukemia", 
          "allogeneic stem cell transplantation", 
          "veno-occlusive disease", 
          "treatment-related mortality", 
          "high-dose chemotherapy", 
          "stem cell transplantation", 
          "overall response rate", 
          "primary refractory", 
          "nonrelapse mortality", 
          "chronic GVHD", 
          "salvage regimen", 
          "fit patients", 
          "acute graft", 
          "host disease", 
          "intensive regimen", 
          "salvage therapy", 
          "primary endpoint", 
          "median age", 
          "dose chemotherapy", 
          "allogeneic group", 
          "predictive factors", 
          "cell transplantation", 
          "grade II", 
          "response rate", 
          "patients", 
          "salvage", 
          "ozogamicin", 
          "regimen", 
          "transplant", 
          "survival", 
          "leukemia", 
          "mortality", 
          "disease", 
          "refractory", 
          "viable option", 
          "years", 
          "GVHD", 
          "chemotherapy", 
          "prognosis", 
          "cytarabine", 
          "transplantation", 
          "graft", 
          "therapy", 
          "mitoxantrone", 
          "incidence", 
          "endpoint", 
          "efficacy", 
          "age", 
          "association", 
          "primary purpose", 
          "safety", 
          "group", 
          "options", 
          "response", 
          "factors", 
          "schedule", 
          "rate", 
          "purpose", 
          "combination", 
          "GO", 
          "bridge", 
          "optimization", 
          "feasible schedule"
        ], 
        "name": "Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia", 
        "pagination": "452-460", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1121220442"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1038/s41409-019-0690-2"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "31554931"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1038/s41409-019-0690-2", 
          "https://app.dimensions.ai/details/publication/pub.1121220442"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-06-01T22:18", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_807.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1038/s41409-019-0690-2"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41409-019-0690-2'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41409-019-0690-2'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41409-019-0690-2'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41409-019-0690-2'


     

    This table displays all metadata directly associated to this object as RDF triples.

    322 TRIPLES      22 PREDICATES      114 URIs      95 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1038/s41409-019-0690-2 schema:about N00e42b43596a4eafb2500089971ada3c
    2 N0434b5232e1e4ba7b4d7a56dbb4e5195
    3 N25485c98d5e24cf0b425f1dd9ef56e88
    4 N27136be04e474355ab393b503d4ef8ef
    5 N58d17dba9adc4cf5919c64b9bae61361
    6 N8ea84646c2d84123a44cdec263bd0ff4
    7 Na698f4175ba64398a7c8675f5bda694d
    8 Nb7bad3a400204a14afa9376899053277
    9 Ncd0d72e7824c44f684624760e0b967ee
    10 anzsrc-for:11
    11 anzsrc-for:1112
    12 schema:author N3ffa7564b1454ac48218a0c99ef1cc3f
    13 schema:citation sg:pub.10.1007/s00277-016-2899-0
    14 sg:pub.10.1038/bmt.2016.130
    15 sg:pub.10.1038/bmt.2016.302
    16 sg:pub.10.1038/leu.2011.13
    17 sg:pub.10.1038/leu.2017.23
    18 sg:pub.10.1038/ncomms12475
    19 sg:pub.10.1038/sj.leu.2403135
    20 sg:pub.10.1038/sj.leu.2404434
    21 sg:pub.10.1186/s13045-017-0498-8
    22 sg:pub.10.2991/chi.d.190218.002
    23 sg:pub.10.2991/chi.d.190316.001
    24 schema:datePublished 2019-09-25
    25 schema:datePublishedReg 2019-09-25
    26 schema:description Optimization of the salvage regimen is required to improve prognosis in primary refractory or relapsed acute myeloid leukemia (AML). In fit patients, a bridge to allogeneic transplant is the primary purpose of salvage. We tested the combination of fractionated gemtuzumab ozogamicin with cytarabine and mitoxantrone (MYLODAM schema) with primary endpoint of efficacy and safety. We also attempted to define predictive factors for survival and response after salvage. We included 58 patients with a median age at salvage of 56 years. The overall response rate was 67%. Leukemia-free survival (LFS) and overall survival (OS) at 2 years was 36% (95% CI: 23–49) and 54% (95% CI: 39–68), respectively. Treatment-related mortality was 7%. Three veno-occlusive diseases (SOS/VOD) occurred during salvage. In the allogeneic group of 28 patients (48%), LFS and OS at 2 years was 57 % (95% CI: 36.3–77.5) and 69 % (95% CI: 49.3–88.7), respectively. Incidences of nonrelapse mortality, grade II–IV acute graft-versus-host disease (GVHD) and chronic GVHD were 16%, 40%, and 45%, respectively. A GO-based intensive regimen is a viable option for salvage therapy and a feasible schedule as a bridge to allogeneic transplant.
    27 schema:genre article
    28 schema:inLanguage en
    29 schema:isAccessibleForFree true
    30 schema:isPartOf N00f145abc3a9418da6866af2ac8fa06e
    31 N1e7ffaa6c54746daa4173b5045ade555
    32 sg:journal.1096890
    33 schema:keywords GO
    34 GVHD
    35 acute graft
    36 acute myeloid leukemia
    37 age
    38 allogeneic group
    39 allogeneic stem cell transplantation
    40 allogeneic transplants
    41 association
    42 bridge
    43 cell transplantation
    44 chemotherapy
    45 chronic GVHD
    46 combination
    47 cytarabine
    48 disease
    49 dose chemotherapy
    50 efficacy
    51 endpoint
    52 factors
    53 feasible schedule
    54 fit patients
    55 gemtuzumab ozogamicin
    56 grade II
    57 graft
    58 group
    59 high-dose chemotherapy
    60 host disease
    61 incidence
    62 intensive regimen
    63 leukemia
    64 leukemia-free survival
    65 median age
    66 mitoxantrone
    67 mortality
    68 myeloid leukemia
    69 nonrelapse mortality
    70 optimization
    71 options
    72 overall response rate
    73 overall survival
    74 ozogamicin
    75 patients
    76 predictive factors
    77 primary endpoint
    78 primary purpose
    79 primary refractory
    80 prognosis
    81 purpose
    82 rate
    83 refractory
    84 regimen
    85 response
    86 response rate
    87 safety
    88 salvage
    89 salvage regimen
    90 salvage therapy
    91 schedule
    92 stem cell transplantation
    93 survival
    94 therapy
    95 transplant
    96 transplantation
    97 treatment-related mortality
    98 veno-occlusive disease
    99 viable option
    100 years
    101 schema:name Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia
    102 schema:pagination 452-460
    103 schema:productId N34f573adbd5648e5bc2c1d611006150f
    104 N4d269926f1ce41c8ab97baa5e3c18fc0
    105 N53cfaf92bfdb4fb3a0e5d19b9dcc732d
    106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1121220442
    107 https://doi.org/10.1038/s41409-019-0690-2
    108 schema:sdDatePublished 2022-06-01T22:18
    109 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    110 schema:sdPublisher N1aa13840f3fd4217a808f47d6e6bc6a1
    111 schema:url https://doi.org/10.1038/s41409-019-0690-2
    112 sgo:license sg:explorer/license/
    113 sgo:sdDataset articles
    114 rdf:type schema:ScholarlyArticle
    115 N00e42b43596a4eafb2500089971ada3c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    116 schema:name Cytarabine
    117 rdf:type schema:DefinedTerm
    118 N00f145abc3a9418da6866af2ac8fa06e schema:volumeNumber 55
    119 rdf:type schema:PublicationVolume
    120 N04198e5221b54bc395f79fe98d72f0cc rdf:first sg:person.01222046703.79
    121 rdf:rest Nf85aa8c74cf549418af8460cff1d5196
    122 N0434b5232e1e4ba7b4d7a56dbb4e5195 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    123 schema:name Humans
    124 rdf:type schema:DefinedTerm
    125 N1aa13840f3fd4217a808f47d6e6bc6a1 schema:name Springer Nature - SN SciGraph project
    126 rdf:type schema:Organization
    127 N1e7ffaa6c54746daa4173b5045ade555 schema:issueNumber 2
    128 rdf:type schema:PublicationIssue
    129 N25485c98d5e24cf0b425f1dd9ef56e88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    130 schema:name Leukemia, Myeloid, Acute
    131 rdf:type schema:DefinedTerm
    132 N27136be04e474355ab393b503d4ef8ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    133 schema:name Antineoplastic Combined Chemotherapy Protocols
    134 rdf:type schema:DefinedTerm
    135 N34f573adbd5648e5bc2c1d611006150f schema:name dimensions_id
    136 schema:value pub.1121220442
    137 rdf:type schema:PropertyValue
    138 N37288358a07644c2b4bd9ed6b65e0220 rdf:first sg:person.01316330650.26
    139 rdf:rest N9520f82db66c47838684dc61da1e2b18
    140 N3785dfcb46b246b99a1c7751ddb4c7f9 rdf:first sg:person.01037550106.72
    141 rdf:rest rdf:nil
    142 N3ffa7564b1454ac48218a0c99ef1cc3f rdf:first sg:person.07456502030.19
    143 rdf:rest N6aa9dd364415484981578486ae15341e
    144 N4d269926f1ce41c8ab97baa5e3c18fc0 schema:name pubmed_id
    145 schema:value 31554931
    146 rdf:type schema:PropertyValue
    147 N4fb3d07fc9544d8ea621f5182d56291c rdf:first sg:person.0774547707.03
    148 rdf:rest N04198e5221b54bc395f79fe98d72f0cc
    149 N53cfaf92bfdb4fb3a0e5d19b9dcc732d schema:name doi
    150 schema:value 10.1038/s41409-019-0690-2
    151 rdf:type schema:PropertyValue
    152 N58d17dba9adc4cf5919c64b9bae61361 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    153 schema:name Hematopoietic Stem Cell Transplantation
    154 rdf:type schema:DefinedTerm
    155 N673dcd1cc7174108b95ea9068f0a70f1 rdf:first sg:person.01176400561.73
    156 rdf:rest N4fb3d07fc9544d8ea621f5182d56291c
    157 N6aa9dd364415484981578486ae15341e rdf:first sg:person.0762572112.39
    158 rdf:rest N37288358a07644c2b4bd9ed6b65e0220
    159 N6f597b152bf4432a8a3d556ed5fec98a rdf:first sg:person.010506014074.64
    160 rdf:rest Ne60d790ff9eb4fe28328e2a9975f1661
    161 N8ea84646c2d84123a44cdec263bd0ff4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Salvage Therapy
    163 rdf:type schema:DefinedTerm
    164 N9520f82db66c47838684dc61da1e2b18 rdf:first sg:person.01025216261.91
    165 rdf:rest N6f597b152bf4432a8a3d556ed5fec98a
    166 N9b819232c03541aaa8d362c809fa5ce6 rdf:first sg:person.0752753564.08
    167 rdf:rest N3785dfcb46b246b99a1c7751ddb4c7f9
    168 Na4c9928de9f84ab1b9110cc661dc58ae rdf:first sg:person.016332521016.91
    169 rdf:rest N673dcd1cc7174108b95ea9068f0a70f1
    170 Na698f4175ba64398a7c8675f5bda694d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    171 schema:name Aminoglycosides
    172 rdf:type schema:DefinedTerm
    173 Nb7bad3a400204a14afa9376899053277 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    174 schema:name Antibodies, Monoclonal, Humanized
    175 rdf:type schema:DefinedTerm
    176 Ncbecb89bf9a641d9b02a0ac9d0838d40 rdf:first sg:person.01362131264.28
    177 rdf:rest Nd72ab9e90b6d4e4a903a2ba5a1ba9c6b
    178 Ncd0d72e7824c44f684624760e0b967ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    179 schema:name Gemtuzumab
    180 rdf:type schema:DefinedTerm
    181 Nd72ab9e90b6d4e4a903a2ba5a1ba9c6b rdf:first sg:person.0644135047.33
    182 rdf:rest N9b819232c03541aaa8d362c809fa5ce6
    183 Ne60d790ff9eb4fe28328e2a9975f1661 rdf:first sg:person.012677511734.74
    184 rdf:rest Na4c9928de9f84ab1b9110cc661dc58ae
    185 Nf85aa8c74cf549418af8460cff1d5196 rdf:first sg:person.01250665275.99
    186 rdf:rest Nfa11a6553ffd438cadaf981b45865435
    187 Nfa11a6553ffd438cadaf981b45865435 rdf:first sg:person.0751372141.23
    188 rdf:rest Ncbecb89bf9a641d9b02a0ac9d0838d40
    189 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    190 schema:name Medical and Health Sciences
    191 rdf:type schema:DefinedTerm
    192 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    193 schema:name Oncology and Carcinogenesis
    194 rdf:type schema:DefinedTerm
    195 sg:journal.1096890 schema:issn 0268-3369
    196 1476-5365
    197 schema:name Bone Marrow Transplantation
    198 schema:publisher Springer Nature
    199 rdf:type schema:Periodical
    200 sg:person.01025216261.91 schema:affiliation grid-institutes:grid.412370.3
    201 schema:familyName Lapusan
    202 schema:givenName Simona
    203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025216261.91
    204 rdf:type schema:Person
    205 sg:person.01037550106.72 schema:affiliation grid-institutes:grid.462844.8
    206 schema:familyName Brissot
    207 schema:givenName Eolia
    208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01037550106.72
    209 rdf:type schema:Person
    210 sg:person.010506014074.64 schema:affiliation grid-institutes:grid.412370.3
    211 schema:familyName Isnard
    212 schema:givenName Francoise
    213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010506014074.64
    214 rdf:type schema:Person
    215 sg:person.01176400561.73 schema:affiliation grid-institutes:grid.412370.3
    216 schema:familyName Hirsch
    217 schema:givenName Pierre
    218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01176400561.73
    219 rdf:type schema:Person
    220 sg:person.01222046703.79 schema:affiliation grid-institutes:grid.412370.3
    221 schema:familyName Battipaglia
    222 schema:givenName Giorgia
    223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01222046703.79
    224 rdf:type schema:Person
    225 sg:person.01250665275.99 schema:affiliation grid-institutes:grid.412370.3
    226 schema:familyName Duléry
    227 schema:givenName Remy
    228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01250665275.99
    229 rdf:type schema:Person
    230 sg:person.012677511734.74 schema:affiliation grid-institutes:grid.412370.3
    231 schema:familyName Adaeva
    232 schema:givenName Rosa
    233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012677511734.74
    234 rdf:type schema:Person
    235 sg:person.01316330650.26 schema:affiliation grid-institutes:grid.412370.3
    236 schema:familyName Mamez
    237 schema:givenName Anne-Claire
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01316330650.26
    239 rdf:type schema:Person
    240 sg:person.01362131264.28 schema:affiliation grid-institutes:grid.412370.3
    241 schema:familyName Vekhoff
    242 schema:givenName Anne
    243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362131264.28
    244 rdf:type schema:Person
    245 sg:person.016332521016.91 schema:affiliation grid-institutes:grid.412370.3
    246 schema:familyName Bonnin
    247 schema:givenName Agnès
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016332521016.91
    249 rdf:type schema:Person
    250 sg:person.0644135047.33 schema:affiliation grid-institutes:grid.462844.8
    251 schema:familyName Mohty
    252 schema:givenName Mohamad
    253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644135047.33
    254 rdf:type schema:Person
    255 sg:person.07456502030.19 schema:affiliation grid-institutes:grid.412370.3
    256 schema:familyName Debureaux
    257 schema:givenName Pierre-Edouard
    258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07456502030.19
    259 rdf:type schema:Person
    260 sg:person.0751372141.23 schema:affiliation grid-institutes:grid.462844.8
    261 schema:familyName Malard
    262 schema:givenName Florent
    263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0751372141.23
    264 rdf:type schema:Person
    265 sg:person.0752753564.08 schema:affiliation grid-institutes:grid.462844.8
    266 schema:familyName Legrand
    267 schema:givenName Ollivier
    268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08
    269 rdf:type schema:Person
    270 sg:person.0762572112.39 schema:affiliation grid-institutes:grid.462844.8
    271 schema:familyName Labopin
    272 schema:givenName Myriam
    273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762572112.39
    274 rdf:type schema:Person
    275 sg:person.0774547707.03 schema:affiliation grid-institutes:grid.412370.3
    276 schema:familyName Delhommeau
    277 schema:givenName Francois
    278 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774547707.03
    279 rdf:type schema:Person
    280 sg:pub.10.1007/s00277-016-2899-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015754901
    281 https://doi.org/10.1007/s00277-016-2899-0
    282 rdf:type schema:CreativeWork
    283 sg:pub.10.1038/bmt.2016.130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017627248
    284 https://doi.org/10.1038/bmt.2016.130
    285 rdf:type schema:CreativeWork
    286 sg:pub.10.1038/bmt.2016.302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023654702
    287 https://doi.org/10.1038/bmt.2016.302
    288 rdf:type schema:CreativeWork
    289 sg:pub.10.1038/leu.2011.13 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021686648
    290 https://doi.org/10.1038/leu.2011.13
    291 rdf:type schema:CreativeWork
    292 sg:pub.10.1038/leu.2017.23 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007318859
    293 https://doi.org/10.1038/leu.2017.23
    294 rdf:type schema:CreativeWork
    295 sg:pub.10.1038/ncomms12475 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008017504
    296 https://doi.org/10.1038/ncomms12475
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1038/sj.leu.2403135 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042288603
    299 https://doi.org/10.1038/sj.leu.2403135
    300 rdf:type schema:CreativeWork
    301 sg:pub.10.1038/sj.leu.2404434 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008085123
    302 https://doi.org/10.1038/sj.leu.2404434
    303 rdf:type schema:CreativeWork
    304 sg:pub.10.1186/s13045-017-0498-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086152596
    305 https://doi.org/10.1186/s13045-017-0498-8
    306 rdf:type schema:CreativeWork
    307 sg:pub.10.2991/chi.d.190218.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113603473
    308 https://doi.org/10.2991/chi.d.190218.002
    309 rdf:type schema:CreativeWork
    310 sg:pub.10.2991/chi.d.190316.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1113600609
    311 https://doi.org/10.2991/chi.d.190316.001
    312 rdf:type schema:CreativeWork
    313 grid-institutes:grid.412370.3 schema:alternateName Service d’Hématologie Clinique et de Thérapie cellulaire, Hôpital Saint Antoine, APHP, Paris, France
    314 Service d’hématologie biologique, Hôpital Saint Antoine, APHP, Paris, France
    315 schema:name Service d’Hématologie Clinique et de Thérapie cellulaire, Hôpital Saint Antoine, APHP, Paris, France
    316 Service d’hématologie biologique, Hôpital Saint Antoine, APHP, Paris, France
    317 Sorbonne Université, Paris, France
    318 rdf:type schema:Organization
    319 grid-institutes:grid.462844.8 schema:alternateName Sorbonne Université, Paris, France
    320 schema:name Service d’Hématologie Clinique et de Thérapie cellulaire, Hôpital Saint Antoine, APHP, Paris, France
    321 Sorbonne Université, Paris, France
    322 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...